Global Chemiluminescence Immunoassay Market to reach USD 12.5 billion by 2027.
Global Chemiluminescence Immunoassay Market is valued approximately USD 7.34 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 7.9 % over the forecast period 2021-2027. Infectious illness, autoimmune disease, cardiovascular disease, diabetes, obesity, and cancer are among the chronic disorders for which chemiluminescence immunoassay (CLIA) solutions are frequently used. CLIA is also utilized for therapeutic medication monitoring by a number of pharmaceutical corporations and research organizations. The rising awareness of early identification of chronic illnesses, as well as pharmaceutical firms' increasing medication discovery and development efforts, are expected to be the market's high-impact key drivers.. Chronic illnesses are the main causes of disability and death across the world. The rate of these disorders is increasing, which is predicted to increase need for appropriate diagnostic techniques such CLIA. According to Globocan data, a total of 18,078,957 new cancer cases were reported worldwide in 2018. Furthermore, the American Diabetes Association estimates that 34.2 million people (10.5 % of the population) in the United States had diabetes in 2018. CLIA is one of the most modern and sophisticated immunoassay methods compared to other conventional approaches including ELISA and RIA, the CLIA approach has numerous benefits. The FDA granted Inova Diagnostics' new QUANTA Flash RF IgA and QUANTA Flash Rheumatoid Factor (RF) IgM chemiluminescent tests 510(k) approval in May 2019. Similarly in August 2018, Mindray Medical International Limited, a Chinese medical equipment company, introduced the CL900i, a fully automated benchtop chemiluminescence immunoassay. During the forecast years, the development of such new solutions is expected to boost market growth. The high-setup cost are difficult to adopt in growing economies such as India, Brazil, and South Africa, which is anticipated to restrain market growth in the forecasting years.


The main regions as Asia Pacific, North America, Europe, Latin America, and the Rest of the World are included in the geographical analysis of the global Chemiluminescence Immunoassay market. During the forecasting period, Asia Pacific is predicted to grow at the fastest CAGR. One of the main reasons driving regional market expansion is a growing awareness of chronic illnesses in emerging economies including China and India. Furthermore, the regional expansion is expected to be driven by the increasing approval of CLIA systems and the debut of innovative CLIA systems by local players. At the China International Medical Equipment Fair in 2018, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., a Chinese medical equipment company, introduced its new CL-6000i CLIA analyzer (CIMEF Spring 2018).

Major market player included in this report are:
DiaSorin S.p.A.
Abbott Laboratories
Shenzhen Mindray Bio-Medical Electronics Co. Ltd.
Immunodiagnostic Systems
Siemens Healthineers
Beckman Coulter Inc.
F. Hoffmann-La Roche AG
Inova Diagnostics Inc.
Maccura Biotechnology Co. Ltd.
Ortho Clinical Diagnostics
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Product:
Instruments
Consumables
Software & Services
By Application:
Therapeutic Drug Monitoring
Oncology
Cardiology
Endocrinology
Infectious Disease
Autoimmune Disease
Others
By End-use:
Hospitals
Clinical Laboratories
Pharmaceutical & Biotechnology Companies
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019
Base year - 2020
Forecast period - 2021 to 2027

Target Audience of the Global Chemiluminescence Immunoassay Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors